Koen Karel Jansen

This inventor holds 5 USPTO granted patents and 3 published patent applications and 3 EPO patents. Top assignees: Abbvie S.a.r.l., Galapagos Nv. Active years: 2017-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Koen Karel Jansen. Retrieved from https://idiyas.com/inventor/koen-karel-jansen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 5 (Patent Applications = 3)

% Patents Active = 60.0

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 27.9

ph-index = 2

Forward Citations = 5(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2017-2020

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10647717 - N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2020-05-12),

2. 10259810 - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2019-04-16),

3. 10130622 - Compounds for treatment of cystic fibrosis (2018-11-20),

4. 9890158 - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2018-02-13),

5. 9796711 - [object Object] (2017-10-24),

Title: Koen Karel Jansen: Innovator in Pharmaceutical Chemistry

Introduction

Koen Karel Jansen is a notable inventor based in Turnhout, Belgium. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target various diseases. With a total of five patents to his name, Jansen's work is recognized for its potential impact on medical treatments.

Latest Patents

Jansen's latest patents include the invention of N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and their methods of use. These compounds are designed to be effective agents in treating diseases and conditions mediated by CFTR, such as cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. The patents also encompass pharmaceutical compositions that include one or more of these compounds, highlighting their therapeutic potential.

Career Highlights

Throughout his career, Jansen has worked with prominent companies in the pharmaceutical industry, including Galapagos NV and AbbVie S.à r.l. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Jansen has collaborated with several professionals in his field, including Rhalid Akkari and Luke Jonathan Alvey. These partnerships have likely enhanced his research and development efforts, leading to successful innovations.

Conclusion

Koen Karel Jansen's contributions to pharmaceutical chemistry through his patents and collaborations demonstrate his commitment to advancing medical science. His work continues to hold promise for the treatment of various diseases, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.